BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 25
• 26
• 27
• 28
• 29

• Drug Development

  Eisai Inc. Release: Lenvatinib Delays Deterioration In Certain Domains Of Quality Of Life In Patients With Unresectable Hepatocellular Carcinoma As Compared To Sorafenib In Phase III REFLECT Study

  September 11, 2017

   · 

  15 min read
• Drug Development

  Berg Presents Key Clinical Data At ESMO 2017 On BPM 31510 For Advanced Pancreatic Cancer Patients And BPM 31543 For Preventing Hair-Loss In Patients Treated With Chemotherapy

  September 11, 2017

   · 

  4 min read
• Evolva Awarded Contract By U.S. Government To Advance Novel Pest Control Product

  September 11, 2017

   · 

  3 min read
• Drug Development

  AstraZeneca PLC’s Tagrisso Shows Potential As A New Standard Of Care In First-Line EGFR-Mutated Lung Cancer At ESMO 2017 Congress

  September 11, 2017

   · 

  10 min read
• Policy

  Bay Area’s Pulse Biosciences Withdraws 510(K) App for Its PulseTx System

  September 11, 2017

   · 

  3 min read
• Bristol-Myers Squibb Release: Opdivo (Nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (Ipilimumab) For Patients With Resected High-Risk Melanoma In Phase III Checkmate -238 Study

  September 11, 2017

   · 

  1 min read
• Genesis Cancercare Queensland Is First In Asia-Pacific Region To Use Elekta’s Venezia Brachytherapy Applicator

  September 11, 2017

   · 

  2 min read
• Drug Development

  Boehringer Ingelheim Release: Safety And Efficacy Results From The INJOURNEY Trial Investigating OFEV (Nintedanib) With Add-On Pirfenidone Provide New Data To Support Nintedanib’s Key Role In IPF

  September 11, 2017

   · 

  5 min read
• Drug Development

  Amgen And Allergan Present Phase III Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress

  September 11, 2017

   · 

  15 min read
• Drug Development

  Idera Pharma Presents Positive Phase I Data For Intratumoral IMO-2125 In Combination With Ipilimumab Demonstrating An Overall Response Rate (ORR) Of 44% In Melanoma Patients Refractory To Anti-PD1 Therapy

  September 11, 2017

   · 

  9 min read